At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 10, 2026 at 06:01 ET
Elevance Health filed an 8-K to publicly reaffirm its full-year 2026 guidance during investor meetings this week. The company confirmed adjusted EPS of at least $26.75 (and GAAP EPS of at least $19.85) and a benefit expense ratio of 90.2% ±50bps. This is a routine FD disclosure with no new financial data or revisions, merely a reiteration of previously stated targets.
- Management reaffirmed full-year 2026 GAAP EPS of at least $19.85 per share, including ~$6.90/share of net unfavorable items.
- Adjusted (non-GAAP) EPS reaffirmed at at least $26.75 per share.
- Full-year 2026 benefit expense ratio guidance reaffirmed at 90.2% plus or minus 50 basis points.
- Guidance does not include any adjustment items beyond those reported in Q1 2026 earnings.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access